As Theravance Biopharma (TBPH) Stock Value Rose, Foundation Asset Management LP Decreased Stake by $638,316; Kames Capital Plc Raised Tetra Tech (TTEK) Holding by $652,832 as Stock Rose

February 13, 2018 - By Dolores Ford

Kames Capital Plc increased its stake in Tetra Tech Inc. (TTEK) by 1.27% based on its latest 2017Q3 regulatory filing with the SEC. Kames Capital Plc bought 14,192 shares as the company’s stock rose 3.90% with the market. The institutional investor held 1.13M shares of the consumer services company at the end of 2017Q3, valued at $52.43 million, up from 1.11 million at the end of the previous reported quarter. Kames Capital Plc who had been investing in Tetra Tech Inc. for a number of months, seems to be bullish on the $2.59 billion market cap company. It closed at $46.4 lastly. It is down 54.98% since February 13, 2017 and is uptrending. It has outperformed by 38.28% the S&P500.

David Charney decreased its stake in Theravance Biopharma Inc (TBPH) by 4.16% based on its latest 2017Q3 regulatory filing with the SEC. Foundation Asset Management Lp sold 18,774 shares as the company’s stock rose 9.03% with the market. The hedge fund run by David Charney held 432,532 shares of the health care company at the end of 2017Q3, valued at $14.81 million, down from 451,306 at the end of the previous reported quarter. Foundation Asset Management Lp who had been investing in Theravance Biopharma Inc for a number of months, seems to be less bullish one the $1.52 billion market cap company. The stock decreased 1.09% or $0.31 during the last trading session, reaching $28.13. About 18,344 shares traded. Theravance Biopharma, Inc. (NASDAQ:TBPH) has risen 89.85% since February 13, 2017 and is uptrending. It has outperformed by 73.15% the S&P500.

Since September 6, 2017, it had 0 insider buys, and 1 insider sale for $451,350 activity.

Investors sentiment decreased to 1.32 in Q3 2017. Its down 0.46, from 1.78 in 2017Q2. It dropped, as 13 investors sold TBPH shares while 18 reduced holdings. 7 funds opened positions while 34 raised stakes. 35.46 million shares or 3.52% more from 34.25 million shares in 2017Q2 were reported. Moneta Invest Advsr Limited Com owns 8,742 shares. Commercial Bank Of America Corporation De reported 60,584 shares. California State Teachers Retirement Sys stated it has 66,851 shares. Financial Bank Of Montreal Can holds 0% or 585 shares. Swiss Comml Bank holds 0% of its portfolio in Theravance Biopharma, Inc. (NASDAQ:TBPH) for 71,342 shares. Credit Suisse Ag reported 0% in Theravance Biopharma, Inc. (NASDAQ:TBPH). Nationwide Fund, a Pennsylvania-based fund reported 23,161 shares. New York State Common Retirement Fund invested in 0% or 46,300 shares. Senzar Asset Ltd Liability invested in 182,100 shares. Sg Americas Limited Liability Corporation holds 0% of its portfolio in Theravance Biopharma, Inc. (NASDAQ:TBPH) for 9,061 shares. Barclays Public Limited owns 2,330 shares. Citigroup has 0% invested in Theravance Biopharma, Inc. (NASDAQ:TBPH). Bnp Paribas Asset Management Hldgs has 174,824 shares. Bancorporation Of Mellon holds 210,331 shares or 0% of its portfolio. D E Shaw And Company accumulated 90,848 shares or 0% of the stock.

Among 8 analysts covering Theravance Biopharma (NASDAQ:TBPH), 7 have Buy rating, 1 Sell and 0 Hold. Therefore 88% are positive. Theravance Biopharma had 20 analyst reports since August 12, 2015 according to SRatingsIntel. Needham maintained Theravance Biopharma, Inc. (NASDAQ:TBPH) on Friday, September 15 with “Buy” rating. The stock has “Buy” rating by Evercore on Monday, August 29. On Monday, October 30 the stock rating was maintained by Robert W. Baird with “Sell”. Needham maintained Theravance Biopharma, Inc. (NASDAQ:TBPH) on Wednesday, August 2 with “Buy” rating. The firm has “Outperform” rating given on Thursday, May 12 by Leerink Swann. As per Thursday, November 3, the company rating was initiated by Piper Jaffray. The rating was maintained by Cantor Fitzgerald with “Buy” on Wednesday, August 16. Robert W. Baird maintained it with “Neutral” rating and $14 target in Wednesday, August 12 report. Robert W. Baird downgraded it to “Underperform” rating and $24 target in Wednesday, October 12 report. The firm has “Buy” rating given on Wednesday, August 16 by Evercore.

Analysts await Theravance Biopharma, Inc. (NASDAQ:TBPH) to report earnings on February, 26. They expect $-1.15 EPS, up 15.44% or $0.21 from last year’s $-1.36 per share. After $-1.27 actual EPS reported by Theravance Biopharma, Inc. for the previous quarter, Wall Street now forecasts -9.45% EPS growth.

Investors sentiment decreased to 1 in 2017 Q3. Its down 0.14, from 1.14 in 2017Q2. It dropped, as 23 investors sold TTEK shares while 85 reduced holdings. 23 funds opened positions while 85 raised stakes. 46.41 million shares or 2.62% less from 47.66 million shares in 2017Q2 were reported. 56,749 were accumulated by Ahl Ptnrs Llp. Advisory Rech accumulated 12,807 shares. 6,270 are owned by Whittier Trust. Ledyard National Bank reported 0.01% stake. Ls Inv Advsrs Llc holds 0.02% or 5,777 shares in its portfolio. Cornercap Counsel Inc holds 0.11% or 17,463 shares in its portfolio. 35,086 are owned by Thrivent Fincl For Lutherans. Jpmorgan Chase & Communications, New York-based fund reported 156,138 shares. Spark Investment Lc owns 134,356 shares or 0.34% of their US portfolio. First Republic Management Inc reported 9,885 shares or 0% of all its holdings. Premier Asset Mgmt Limited Liability Corp holds 161,505 shares or 1.69% of its portfolio. Parkside Bancorporation Tru owns 797 shares for 0.01% of their portfolio. Franklin Resource reported 155,000 shares. Boston Prtn accumulated 0.06% or 1.03M shares. Da Davidson & owns 10,000 shares or 0.01% of their US portfolio.

Among 13 analysts covering TETRA Tech (NASDAQ:TTEK), 7 have Buy rating, 0 Sell and 6 Hold. Therefore 54% are positive. TETRA Tech had 32 analyst reports since November 9, 2015 according to SRatingsIntel. The stock of Tetra Tech, Inc. (NASDAQ:TTEK) earned “Perform” rating by Oppenheimer on Monday, April 18. The firm earned “Buy” rating on Wednesday, August 9 by Canaccord Genuity. On Wednesday, January 25 the stock rating was initiated by Roth Capital with “Buy”. Canaccord Genuity maintained Tetra Tech, Inc. (NASDAQ:TTEK) rating on Tuesday, June 6. Canaccord Genuity has “Buy” rating and $5200 target. The company was maintained on Thursday, August 3 by Boenning & Scattergood. The firm has “Buy” rating given on Monday, November 9 by Wunderlich. The rating was maintained by Stifel Nicolaus with “Hold” on Sunday, August 6. The rating was maintained by Canaccord Genuity on Monday, June 26 with “Buy”. The firm has “Buy” rating by Canaccord Genuity given on Tuesday, May 31. As per Tuesday, January 5, the company rating was reinitiated by Stifel Nicolaus.

Kames Capital Plc, which manages about $3.65B US Long portfolio, decreased its stake in Microsoft Corporation (NASDAQ:MSFT) by 266,492 shares to 225,206 shares, valued at $16.76 million in 2017Q3, according to the filing. It also reduced its holding in Raytheon Company (NYSE:RTN) by 3,865 shares in the quarter, leaving it with 6,619 shares, and cut its stake in Merck Co. Inc. (NYSE:MRK).

Since October 24, 2017, it had 0 insider purchases, and 8 insider sales for $5.80 million activity. Another trade for 4,037 shares valued at $186,362 was sold by BROWNLIE WILLIAM R. 14,112 Tetra Tech, Inc. (NASDAQ:TTEK) shares with value of $705,600 were sold by CHU RONALD J. MCDONALD KEVIN P sold $277,411 worth of stock. 8,000 Tetra Tech, Inc. (NASDAQ:TTEK) shares with value of $399,267 were sold by LEWIS J CHRISTOPHER.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>